Cholesterol Clinical Trials
Here are the 6 most popular medical studies for cholesterol
Electronic Alerts for High Cholesterol
This trial is focused on the feasibility of implementing an electronic alert system to notify patients and doctors of high LDL-C values. 400 patients will be randomly selected to either receive notifications or not.
HMG-CoA Reductase Inhibitor
Rosuvastatin and Gut Microbiome in Healthy Subjects
This trial will study how rosuvastatin affects gut bacteria and cholesterol levels. 100 healthy volunteers will be enrolled over 2 years, with 4 study visits during that time.
HMG-CoA Reductase Inhibitor
Statin for Hemoglobinuria
Statins are a class of drugs that are the most commonly prescribed medications in developing countries. Statins act on the enzyme HMG-CoA reductase to inhibit its conversion to mevalonate, a precursor for cholesterol synthesis. Subsequently statins are prescribed to patients with relatively high blood cholesterol levels. However, taking statins does not come without side effects. Most notably, the effects of statins on muscle wasting have been studied extensively. This includes up-regulation of the ubiquitin proteasome system, muscle cell damage and rhabdomyolysis, elevated creatine kinase, and mitochondrial dysfunction. Due to the negative side effects of statin therapy, additional therapies are warranted to help offset the effects on muscle wasting. Loss of muscle mass is a significant concern as it is associated with a reduction in muscle strength and power (Ferrando et al., 1996; Creditor, 1993). This condition is observed in aging, disease states, and long periods of unloading such as hospital admission and can lead to disability, increased falls, loss of independence, and mortality. Subsequently, there is a critical need to develop interventions to counteract this loss of muscle mass and strength. Exercise is one such intervention, however, in some cases may not be a feasible option. For instance, exercise has been demonstrated to exacerbate the muscle side of effects of statins. Subjects complain of increased muscle soreness and have elevated creatine kinase levels and they also do not want to take statins anymore (Kearns et al., 2008; Parker et al., 2012; Sinzinger et al., 2004). Because of this limitation, there is a critical need to develop other interventions that can prevent the loss of muscle mass during statin use.
Popular filter options for cholesterol trials
Hypercholesterolemia Clinical Trials
View 31 Hypercholesterolemia medical studies.
Behavioral Intervention
Church-based Health Intervention for Cardiovascular Disease
This trial studies the impact of two approaches to reduce CVD disparities in Black communities in Louisiana. One is a CHW-led multifaceted intervention, the other is a group-based education strategy.
High Cholesterol Clinical Trials
View 26 High Cholesterol medical studies.
Behavioral Intervention
Church-based Health Intervention for Cardiovascular Disease
This trial studies the impact of two approaches to reduce CVD disparities in Black communities in Louisiana. One is a CHW-led multifaceted intervention, the other is a group-based education strategy.
Phase 3 Cholesterol Clinical Trials
View 47 phase 3 cholesterol medical studies.
Cholesteryl Ester Transfer Protein (CETP) Inhibitor
Obicetrapib for High Cholesterol
This trial will study whether the drug obicetrapib is effective in treating people with a history of HeFH, a condition that causes high cholesterol. The trial will be placebo-controlled, meaning some participants will receive a placebo, and double-blind, meaning neither the participants nor the researchers will know who is receiving the drug or the placebo.
Cholesterol Clinical Trials With No Placebo
View 47 cholesterol medical studies that do not have a placebo group.
Behavioral Intervention
Church-based Health Intervention for Cardiovascular Disease
This trial studies the impact of two approaches to reduce CVD disparities in Black communities in Louisiana. One is a CHW-led multifaceted intervention, the other is a group-based education strategy.
Behavioural Intervention
TEAM-based Care for Cancer
This trial will test a new way of managing care for cancer patients with comorbidities. 800 patients will be randomly assigned to either usual care or care that includes their primary care physician as an active member of their cancer care team. The goal is to improve chronic disease management and communication among cancer survivors.
View More Cholesterol Trials
See another 29 medical studies focused on cholesterol.
Frequently Asked Questions
Introduction to cholesterol
What are the top hospitals conducting cholesterol research?
When it comes to cutting-edge clinical trials focused on cholesterol management, Novartis Investigative Sites are leading the way in various locations across the United States. In Boca Raton, researchers are currently conducting three active cholesterol trials, marking their dedication to finding innovative solutions for this prevalent condition. Interestingly, their first recorded cholesterol trial dates back to 2021, demonstrating their commitment to staying ahead of emerging health concerns.
Moving northwards to Birmingham and Richmond, Novartis Investigative Sites continue their vital work in advancing our understanding of cholesterol with two ongoing trials at each location. Impressively, even with a shorter history in this field compared to other sites, these hospitals have already conducted a notable number of all-time cholesterol studies.
Meanwhile Shreveport and Atlanta also play significant roles within the research landscape surrounding cholesterol management. Both sites have two active cholesterol trials underway as they contribute towards unraveling new insights into this pervasive health challenge. It is worth highlighting that these institutions initiated their respective involvement in studying high levels of blood lipids only recently; recording their first-ever tests focusing on tackling such issues from 2023 onwards
These diverse Novartis Investigative Sites demonstrate impressive progress and collaboration when it comes to battling high cholesterol levels that impact millions worldwide. Through ongoing efforts and groundbreaking discoveries generated by these clinical trials across different locations throughout America; scientists hope not only to find more effective treatments but also improve overall cardiovascular health outcomes for individuals struggling with lipid disorders
Which are the best cities for cholesterol clinical trials?
Cincinnati, Ohio; Boca Raton, Florida; and New york, New York are among the best cities for cholesterol clinical trials. Cincinnati leads with 12 active trials focused on treatments like Active, lerodalcibep, and Inclisiran. Boca Raton follows closely behind with 7 ongoing studies examining interventions such as Inclisiran, MK-0616, and Obicetrapib. Similarly, New York City also has 7 active trials investigating various cholesterol-lowering treatments including 4-Week LDL-Cholesterol (LDL-C)-Reduction Treatment, Inclisiran, and Obicetrapib. These three cities offer individuals opportunities to participate in cutting-edge research aimed at advancing our understanding of cholesterol management and promoting better health outcomes.
Which are the top treatments for cholesterol being explored in clinical trials?
Clinical trials are paving the way for new advancements in cholesterol treatment. Inclisiran, a promising drug with four ongoing clinical trials, is leading the pack. Since its introduction in 2017, it has garnered attention with a total of 12 cholesterol-related trials. Another contender making waves is MK-0616, currently being explored in two active trials and five all-time cholesterol studies since its listing in 2022. Equally noteworthy is obicetrapib, entering the scene in 2021 and already gaining traction with two ongoing trials and five all-time cholesterol studies under its belt. These treatments hold great potential to improve outcomes for individuals battling high cholesterol levels.
What are the most recent clinical trials for cholesterol?
Exciting developments are underway in the field of cholesterol management, with recent clinical trials offering potential breakthroughs. One such trial involves 2-Hydroxybenzylamine (2-HOBA), a promising compound being studied in Phase 2 for its effectiveness in managing cholesterol levels. Additionally, MK-0616 has shown promise as a potential treatment option for high cholesterol, with Phase 3 trials demonstrating positive outcomes. Another Phase 3 study investigated the efficacy of Inclisiran and Inclisiran Sodium 300mg on lowering cholesterol levels. These advancements highlight the ongoing efforts to find innovative solutions for individuals battling elevated cholesterol and pave the way towards improved treatments in the future.
What cholesterol clinical trials were recently completed?
Recent advancements in cholesterol research have been supported by a multitude of completed clinical trials. Notably, Merck Sharp & Dohme Corp.'s trial exploring the potential of MK-0616 concluded in March 2022. In April 2021, LIB Therapeutics LLC wrapped up their promising study on lerodalcibep. Earlier milestones include Regeneron Pharmaceuticals' completion of an evinacumab trial in June 2020 and LIB Therapeutics LLC's previous successful investigation into lerodalcibep, finalized in December 2019. Additional significant contributions were made with the completion of Novartis' Inclisiran Sodium trial in April 2019 and Sanofi's Ezetimibe trial concluding in May 2018. The wealth of data from these diverse studies drives forward our understanding and treatment options for managing cholesterol-related conditions.